# Final Autonomous Operations Audit — CLOSE

Date: 2026-08-26
Status: **PASS / CLOSED**

## Scope
This close report records the final audit of unattended operation, quant governance, lifecycle review, Forward→Production gating, post-Production health review, UI action guidance, failure visibility, free-operation practicality, execution causality, market-regime behavior, and repository/workflow hygiene.

The governing charter is `research/final-operations-audit-charter-2026-08-26.md`.

## Acceptance decision
**PASS.** No material acceptance blocker remains in the audited architecture.

This does **not** mean that any challenger has earned Production status. Phase 5 evidence is still accumulating and Production remains human-gated.

## Authoritative acceptance evidence

### Final Operational Acceptance
- Workflow: `Final Operational Acceptance`
- Run ID: **32920231014**
- Job ID: **98032225970**
- Head SHA: **5f721d1fcf07b39d7cf307409b9441fd2ceb28dd**
- Conclusion: **SUCCESS**

Successful gates:
1. Full core acceptance suite.
2. Integrated Pages build.
3. Lifecycle and Production-health state generation.
4. Current autonomous-state validation.
5. Live execution-causality and stale-review UI guards.
6. Scheduled-workflow surface and recovery cadence.
7. Historical research workflows frozen to manual-only.
8. Daily operational-test isolation.
9. Temporary migration/finalizer cleanup boundary.
10. PWA public-data cache policy.

The same core suite had previously produced 78/78 passing tests; the final accepted run again completed the full core suite successfully.

### Current Phase 5 operational workflow
A later workflow-only Phase 5 alignment is supported separately rather than being mixed into the earlier acceptance SHA:
- Workflow: `Phase 5 Forward Gate`
- Run ID: **32920310307**
- Job ID: **98032461141**
- Head SHA: **a5f6df620156de83029368e84f79f33226f6ce07**
- Conclusion: **SUCCESS**

It successfully completed focused operational regression tests, true-Forward generation, append-only persistence, Pages build/deployment, and final enforcement checks.

### Autonomous Lifecycle operational workflow
- Workflow run ID: **32919963485**
- Job ID: **98032229823**
- Conclusion: **SUCCESS**
- Persisted `lifecycle-review.json` and `production-health-review.json` to main and deployed Pages.

### Daily operational evidence
- Daily run ID: **32919886109**
- Job ID: **98031222616**
- Conclusion: **SUCCESS**
- Data generation, calculation tests, append-only persistence, Pages build/deployment, and failure-marker enforcement all succeeded.

## Current system state
At close:
- Platform mode: **RESEARCH**
- Human-approved Production: **false**
- Lifecycle stage: **ACCUMULATING**
- System decision: **ACCUMULATING**
- User action: **NONE**
- Next review: **2027-02-25**
- Production Health: **NOT_ACTIVE**
- No automatic Production change occurred.

Frontier under lifecycle review:
1. TQQQ — `VS13-v1.0` — incumbent
2. UPRO — `UPRO-SPBT-v1.0`
3. SSO — `SSO-SPBT-Scaled-v1.0`
4. QLD — `QLD-VS13-Scaled-v1.0`

## Phase 5 first-bar status
The Phase 5 workflow is healthy (`status=success`, no errors), but the three new challengers are currently `AWAITING_FIRST_BAR` because the common input set has not yet aligned through the Forward start date: leveraged ETFs/VIX have newer data while SPY/QQQ public history is lagging.

This is **not backfilled**. The pre-open recovery schedule will retry. When data becomes available, the execution-causality guard uses the first legally observable future market open rather than pretending an already-passed open was tradable.

## Material issues found and fixed during this audit

### 1. Missing autonomous Review Engine
Before this audit, review dates/evidence could be displayed but there was no deterministic lifecycle judgment engine.

Fixed with:
- `lib/lifecycle-review.ts`
- `scripts/generate-lifecycle-review.ts`
- append-only lifecycle events
- automated INTERIM / FORMAL / STRONGER decisions

### 2. Phase 5 candidates could not enter the guarded Production registry
UPRO-SPBT, SSO-SPBT-Scaled, and QLD-VS13-Scaled were not registered for a future human-approved Production transition.

Fixed by registering exact frozen Ticker × Strategy × Version combinations without activating them.

### 3. Human approval could have been disconnected from the new Phase 5 Forward gate
Production approval now requires:
- FORMAL or STRONGER lifecycle stage;
- `PHASE6_HUMAN_DECISION_REQUIRED`;
- currently eligible frozen version;
- DECISION state first;
- exact `APPROVE PRODUCTION` human confirmation.

No historical score can substitute for the true-Forward gate.

### 4. No persistent post-Production quarterly health-review history
Added append-only Production Health Review with:
- Healthy / Watch / Revalidation Required / Critical;
- quarterly due dates;
- late-review detection;
- no fabricated retrospective health state;
- no automatic strategy replacement.

### 5. Live Signal UI could display a passed theoretical t+1 open
Forward accounting already protected causality, but the user-facing live signal could still show the theoretical next open.

Fixed so both live Signal and Forward use the first legal execution date based on actual record availability. The UI reads the causality-guarded `signal.executionDate`.

### 6. Public data can lag after the US close
Added bounded recovery runs before the next US open:
- Daily Signal: post-close + pre-open recovery
- Phase 5: post-close + pre-open recovery

No retrospective fill is permitted if data arrives after the open.

### 7. Old “no action” review could remain visible if review automation stopped
Added a 48-hour Lifecycle Review stale guard. A stale review invalidates old `NONE` guidance and instructs the user to inspect Actions before changing Production or adding risk.

### 8. Turnover definition ambiguity
Lifecycle Production gating now uses explicit **Action Days/year** for Phase 5 candidates rather than substituting raw execution count.

### 9. Routine CI was unnecessarily re-running expensive historical research
Added a focused `test:ops` suite for routine Daily/Phase 5 operation. Full historical/core tests remain in research/final acceptance paths.

### 10. Closed research workflows could still consume Actions or invite repeated mining
Phase 1, 1.5, 2, 3, 4, historical weekly research, and legacy Track B are manual-only. Their evidence remains in the repository for auditability.

### 11. Temporary migration/finalization workflows increased maintenance risk
Completed installer/migration/finalizer workflows and helper scripts were removed after successful use. Research outputs and commit history remain as the audit trail.

## Scheduled autonomous surface
Normal recurring automation is intentionally narrow:

### Daily Signal
- post-close: `30 22 * * 1-5`
- pre-open recovery: `0 13 * * 2-6`

### Phase 5 Forward
- post-close: `45 22 * * 1-5`
- pre-open recovery: `15 13 * * 2-6`

### Lifecycle Review
- daily: `15 1 * * *`

All historical research workflows are manual-only.

## Review policy
### 2027-02-25 — Interim
- informational gate only;
- promotion prohibited;
- healthy result => continue Forward;
- integrity/data problem => user review required.

### 2027-08-25 — Formal
First possible Phase 6 human decision gate.

A candidate cannot become eligible without sufficient live observations, natural non-zero-turnover execution evidence, multiple regimes, acceptable missing-data rate, Action Days <= 40/year, DD remaining inside the frozen adverse envelope, and healthy integrity.

Insufficient evidence extends Forward; parameters are not changed to manufacture eligibility.

### 2028-08-25 — Stronger
Same architecture with stronger accumulated Forward evidence.

## Regime / failure acceptance coverage
The four frontier systems were checked across:
- bull
- bear
- sideways
- crash
- recovery
- high volatility
- low volatility

Additional safeguards tested include:
- delayed provider data
- no retroactive open fills
- New York DST handling
- weekends
- append-only Forward
- duplicate prevention
- freeze drift prevention
- pre-start Forward exclusion
- review-event non-duplication
- Production registry/config drift
- human-approval bypass prevention
- quarterly health-review lateness

## Residual risks / limitations
No software audit can remove external dependency risk. Remaining non-blocking risks include:
- public Nasdaq/Cboe data delays or methodology/API changes;
- GitHub Actions or GitHub Pages outages;
- scheduled workflows are best-effort rather than exchange-grade scheduling;
- ETF/index methodology, liquidity, leverage mechanics, market structure, taxes, and real broker execution can change;
- current historical/OOS evidence is not pristine independent future evidence.

These are handled through visibility, causality guards, no-backfill rules, Forward accumulation, lifecycle review, and human Production approval rather than by claiming they do not exist.

## Final user action
**NONE.**

The correct current action is to leave the system in Phase 5 and allow true Forward evidence to accumulate. The application should surface a user action only when a review/failure/Production-health condition requires one.
